| Document |
Document Title |
|
JP5125076B2 |
|
|
JP2013010773A |
To provide a prodrug including an NO-releasing prodrug a double prodrug, and mutual prodrug, in which bio-cleavable linker and a remedy are linked covalently.There is provided a compound of formula (I) or a pharmaceutically acceptable sa...
|
|
JP2013500962A |
Compounds of formula (I) and pharmaceutical compositions containing them are described. The use of the compounds and compositions are also described.
|
|
JP5113745B2 |
The present invention provides processes for the production of docetaxel. Docetaxel is produced by protecting the C(7) and the C(10) hydroxy groups of 10-DAB with a bridging silicon-based protecting group. The resulting 7,10-protected 10...
|
|
JP5115477B2 |
Disclosed is a 3-ethyloxethane compound having a hydroxyl group which is represented by the following general formula (1). (1) (In the formula, A represents an alkylene group having 3-5 carbon atoms which may have an ether bond or an alk...
|
|
JP5098328B2 |
|
|
JP5098322B2 |
To provide a method for producing an oxetane compound with high selectivity which is achieved by subjecting a trimethylolalkane to an intramolecular dehydration reaction in the presence of a solid catalyst. The method for producing an ox...
|
|
JP5087260B2 |
A polymerizable liquid crystal compound is represented by the following formula (1): P-Sp1-L1-M1-L2-Sp2-Ox (1) wherein P represents a polymerizable group; one of Sp1 and Sp2 represents a branched alkylene group, or an alkylene grou...
|
|
JP5084503B2 |
A compound of the formula (I): wherein each symbol is as defined in the description, a salt thereof, and a prodrug thereof of the present invention unexpectedly have a superior GPR40 receptor agonist activity and superior properties as p...
|
|
JP5076414B2 |
The compound provided by the present invention is a polymerizable optically active compound represented by Formula (1): wherein R1 is hydrogen, chlorine or bromine; R2 is hydrogen, methyl or ethyl; A1 is 1,4-phenylene, biphenyl-4,4'-diyl...
|
|
JP5073912B2 |
This invention is directed to prodrugs that can be activated at the preferred site of action in order to selectively deliver the corresponding therapeutic parent drugs to target cells or to the target site. This invention will therefore ...
|
|
JP2012528086A |
Calcium-sensing receptor (CaSR) modulating substituted cyclopentylene compounds represented in formula I (wherein X is CH or N) and pharmaceutical compositions thereof are useful for treating diseases.
|
|
JP2012214424A |
To provide a process for highly productively producing a monohydroxy monoether compound.The process for producing a monohydroxy monoether compound includes reacting a hydrocarbon compound (1) of R1-CH2-X (1) having a leaving group X with...
|
|
JP2012214468A |
To provide a novel compound having a preventive activity on hazardous arthropods.An amide compound is provided which is represented by formula (I) and which has excellent effect of prevention of hazardous arthropods, wherein Y is a 3 to ...
|
|
JP5068743B2 |
A process for the preparation of 10-deacetyl-7,10-bis-trichloroacetylbaccatine III with HPLC purity higher than 99% and free from 2-debenzoyl-2-pentenoylbaccatine III by purification of 10-deacetyl-7,10-bis-trichloroacetylbaccatineIII fo...
|
|
JP5065550B2 |
|
|
JPWO2010123016A1 |
To provide a compound having a GPR40 agonist action, which is useful as a pharmaceutical composition, an insulin secretagogue, and a preventive / therapeutic agent for diabetes. As a result of diligent studies on a compound having a GPR4...
|
|
JP5042835B2 |
Provided are a polymerizable group-containing and fluorine-containing adamantane derivative capable of affording a cured product having good heat resistance, good mechanical properties such as surface hardness and a low refractive index,...
|
|
JP2012520276A |
There is provided compounds of formula I, wherein Y, ring A, Da, Db, D2, D3, L1, Y1, L2, Y2, L3 and Y3 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of ...
|
|
JP5010279B2 |
The acetone solvate (A) of 4-acetoxy-2alpha -benzoyloxy-5beta ,20-epoxy-1-hydroxy-7beta ,10beta -dimethoxy-9-oxo-tax-11-en-13alpha -yl (2R,3S)-3-tert. butoxycarbonylamino-2-hydroxy-3-phenylpropionate (I) (i.e. dimethoxy docetaxel) (prefe...
|
|
JP5008783B2 |
The present invention is directed compositions of the formula: (I) wherein: D is a biologically active moiety; X is an electron withdrawing group; Y and Y' are independently O or S; R1 is selected from the group consisting of H, C1-6 alk...
|
|
JP5000195B2 |
|
|
JP2012517978A |
The invention relates to the use of compounds of formula I wherein the substituents are described in the description and claims for the treatment of psychoses, dysfunction in memory and learning, schizophrenia, dementia, attention defici...
|
|
JP4997318B2 |
The present invention is a method of preventing or reducing atherosclerosis or restenosis, and a pharmaceutical preparation used therefore. In particular, it is a method of preventing or reducing atherosclerosis or restenosis after arter...
|
|
JP2012140465A |
To provide new derivatives of 10-deacetylbaccatine III and 10-deacetyl-14β-hydroxybaccatine III having cell toxicity and antitumoral activity.The derivatives are prepared starting from so-called synthons or from other taxanes of natural...
|
|
JP4986354B2 |
Seco-baccatin III derivatives of formula: wherein R, R1-R4, R1 R', R11 R'', and R111 R''' are disclosed herein; pharmaceutical compositions comprising seco-baccatin III derivative; and methods for treating cancer, arthritis, and inhibiti...
|
|
JP4979242B2 |
|
|
JP4971169B2 |
The invention relates to a process for the preparation of 10-deacetyl-N-debenzoyl-paclitaxel ( I ) a synthon useful for the preparation of taxanes with antitumour activity, and intermediates for the preparation thereof. The invention als...
|
|
JP2012116821A |
To provide a paclitaxel derivative which not only exhibits high water solubility but also retains an outstanding anti-cancer activity, and to provide a medicine formed of the paclitaxel derivative and an anticancer agent including the pa...
|
|
JP4957010B2 |
|
|
JP4947219B2 |
The present invention relates to a composition for use in an organic device, comprising at least two cross-linking compounds, wherein each of the at least two cross-linking compounds is a polymer that has a hole-transporting site and con...
|
|
JP4942871B2 |
The present invention concerns a new general process for asymmetric hemisynthesis of harringtonines and their analogs, that are alkaloids used in chemotherapy. This process comprises direct esterification of a natural cephalotaxine with ...
|
|
JP4940754B2 |
|
|
JP4943011B2 |
|
|
JP4934971B2 |
|
|
JP2012092329A |
To provide a base generator with less occurrence of outgas or odor when in use, and to provide a photosensitive resin composition applicable to various polymeric precursors and having less occurrence of outgas or odor when in use.The bas...
|
|
JP4927535B2 |
A composition for delivering a tumor therapeutic agent to a patient includes a fast-release formulation of a tumor apoptosis inducing agent, a slow-release formulation of a tumor therapeutic agent, and a pharmaceutically acceptable carri...
|
|
JP2012509878A |
The present invention provides methods of sensitizing cancer cells to docetaxel and inhibiting the growth of various tumors by employing a modified eIF-4E antisense oligonucleotide and docetaxel in combination.
|
|
JP4924783B2 |
|
|
JP4920353B2 |
The present invention provides compositions comprising an anti-angiogenic factor, and a polymeric carrier. Representative examples of anti-angiogenic factors include Anti-Invasive Factor, Retinoic acids and derivatives thereof, and taxol...
|
|
JP4911844B2 |
A novel liquid crystalline compound by the formula: Z<1>-(CH2)n-L<1>-P<1>-L<2>-P<2>-L<3>-P<3>-L<4>-(CH2)m-Z<2> wherein Z<1> and Z<2> are each independently a group represented by any one of formulas (2), (3) and (4) below, L<1>, L<2>, L<...
|
|
JP4907043B2 |
A process for the preparation of 14 beta-hydroxy-1,4-carbonate-deacetylbaccatin III and intermediates useful for the preparation of novel taxan derivatives with antitumor activity are disclosed.
|
|
JP4899386B2 |
|
|
JP4899385B2 |
|
|
JP4890455B2 |
Methods for obtaining paclitaxel from plants containing paclitaxel are disclosed. Plant material is first obtained from plants containing paclitaxel. Paclitaxel is then extracted from the plant material. Subsequently, paclitaxel is separ...
|
|
JP4884228B2 |
The invention relates to a second-generation-fatty acid conjugate and pharmaceutical compositions thereof. The second-generation-fatty acid conjugate are useful in the treatment of cancer in a human in need thereof.
|
|
JP2012036156A |
To provide a new polyvalent oxetane vinyl ether compound which is useful as a polymerizable monomer in the fields of optical waveguides, nanoimprint, hologram, and the like, and to provide a method for producing the same.There is provide...
|
|
JP2012036155A |
To provide a new bis(oxetane vinyl ether) compound which is useful as a polymerizable monomer in the fields of optical waveguides, nanoimprint, hologram, and the like, and to provide a method for producing the same.There is provided the ...
|
|
JP2012036152A |
To provide a new oxetane vinyl ether compound which is useful as a polymerizable monomer in the fields of optical waveguides, nanoimprint, hologram, and the like, is also useful as an intermediate for other polymerizable monomers, and ha...
|
|
JP4874102B2 |
The present invention relates to new taxane analogs useful for the treatment of cancer as well as methods for producing the same. The chemical compounds according to the present invention have the general Formula (I) wherein R 1 and R 2 ...
|
